Primary systemic therapy in HER2-amplified breast cancer: A clinical review

Expert Review of Anticancer Therapy

Volumn 12, Issue 8, 2012, Pages 1005-1013

  Khasraw, Mustafa ^a,b   Bell, Richard ^a,b  

^a DEAKIN UNIVERSITY   (Australia)

^b GEELONG HOSPITAL   (Australia)

Author keywords

HER2 positive breast cancer; neoadjuvant chemotherapy; primary systemic therapy; trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; GOSERELIN; LAPATINIB; LETROZOLE; METHOTREXATE; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENE; GENE AMPLIFICATION; GENE FUNCTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATHOLOGICAL COMPLETE RESPONSE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; PACLITAXEL; PYRAZOLES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; SULFONAMIDES; TAXOIDS;

EID: 84867041982     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.62     Document Type: Review

References (45)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24(12), 1940-1949 (2006).
2. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monographs (30), 96-102 (2001).
3. Bear HD, Anderson S, Brown A et al.; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 21(22), 4165-4174 (2003).
4. Gradishar WJ, Wedam SB, Jahanzeb M et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann. Oncol. 16(8), 1297-1304 (2005).
5. von Minckwitz G, Eidtmann H, Loibl S et al.; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust Investigators. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann. Oncol. 22(2), 301-306 (2011).
6. Baselga J, Bradbury I, Eiremann H et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res. 70(24 Suppl.) S3-3 (2010).
7. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007).
8. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 30(8), 1426-1447 (2008).
9. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28(1), 92-98 (2010).
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
11. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27(8), 1323-1333 (2009).
12. Wolff AC, Hammond ME, Schwartz JN et al.; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
13. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br. J. Cancer 94(3), 358-362 (2006).
14. Mazouni C, Peintinger F, Wan-Kau S et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J. Clin. Oncol. 25(19), 2650-2655 (2007).
15. Berruti A, Generali D, Kaufmann M et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J. Natl Cancer Inst. Monographs 2011(43), 147-151 (2011).
16. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am. J. Clin. Oncol. 16(3), 223-228 (1993).
17. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J. Am. Coll. Surg. 180(3), 297-306 (1995).
18. von Minckwitz G, Kümmel S, Vogel P et al.; German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J. Natl. Cancer Inst. 100(8), 542-551 (2008).
19. Berruti A, Generali D, Bertaglia V et al. Intermediate endpoints of primary systemic therapy in breast cancer patients. J. Natl. Cancer Inst. Monographs 2011(43), 142-146 (2011).
20. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23(16), 3676-3685 (2005).
21. Buzdar AVV, Ibrahim NK, Theriault RL et al. Seventy-two month update of randomized trial of preoperative therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy with or without concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer. ASCO Breast Cancer Symp. (Abstract 221) (2009).
22. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712), 377-384 (2010).
23. Semiglazov V, Eiermann W, Zambetti M et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the Neoadjuvant Herceptin (NOAH) study. Eur. J. Surg. Oncol. 37(10), 856-863 (2011).
24. Untch M, Fasching PA, Konecny GE et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2 overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J. Clin. Oncol. 29(25), 3351-3357 (2011).
25. Pierga JY, Delaloge S, Espiè M et al. A multicenter randomized Phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res. Treat. 122(2), 429-437 (2010).
26. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J. Clin. Oncol. 28(12), 2024-2031 (2010).
27. Loibl S, Bruey J, Von Minckwitz G et al. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study. ASCO Meeting Abstr. 29(15 Suppl.), 530 (2011).
28. Witzel I, Loibl S, von Minckwitz G et al. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res. Treat. 123(2), 437-445 (2010).
29. Sikov WM, Dizon DS, Strenger R et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J. Clin. Oncol. 27(28), 4693-4700 (2009).
30. Rosen LS, Ashurst HL, Chap L. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 15(3), 216-235 (2010).
31. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28(7), 1138-1144 (2010).
32. Schneeweiss A, Chia S, Hickish T et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized Phase II study (TRYPHAENA). Cancer Res. 71(Suppl. 24), 112S (2011).
33. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase 2 trial. Lancet Oncol. 13(1), 25-32 (2012).
34. Gianni L, Pienkowski T, Im YH et al. P301 addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: result of a randomised Phase II study (NEOSPHERE). Breast 20, S73-S73 (2011).
35. Gamez C, Flamen P, Holmes E et al. 5013 ORAL FDG-PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer patients: the Neo-ALTTO study results. Eur. J. Cancer 47, S333-S334 (2011).
36. Guarneri V, Frassoldati A, Bottini A et al. Final results of a Phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). ASCO Meet. Abstr. 29 (15 Suppl.), 507 (2011).
37. Chang JCN, Mayer IA, Forero-Torres A et al. TBCRC 006: a multicenter Phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. ASCO Meet. Abstr. 29(15 Suppl.), 505 (2011).
38. Yardley DA, Raefsky E, Castillo R et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin. Breast Cancer 11(5), 297-305 (2011).
39. Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13(4), 1198-1207 (2007).
40. Esteva FJ, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 177(4), 1647-1656 (2010).
41. Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?. Curr. Oncol. Rep. 13(1), 17-25 (2011).
42. Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol. 26(7), 1059-1065 (2008).
43. Rasmussen BB, Regan MM, Lykkesfeldt AE et al.; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 9(1), 23-28 (2008).
44. Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer?. A clinical review. Breast 21(2), 142-149 (2012).
45. von Minckwitz G, Untch M, Blohmer J-U et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30(15), 1796-1804 (2012).